Core Insights - Microbial protein is emerging as a new, nutritious, and efficient alternative protein source, driven by technological advancements and increasing demand for high-quality protein in China [1][2] - The market for microbial protein is projected to reach approximately 60 billion yuan by 2035, with growth catalyzed by technological progress and potential policy support [2] - Key players in the industry include innovative startups and traditional leaders, each leveraging their strengths in technology and capital to capture market opportunities [3][4] Industry Overview - The demand for high-quality protein in China is rising, while supply is constrained by reliance on imported plant proteins and limited animal protein production [1] - Microbial protein, as a subset of alternative proteins, offers superior nutritional profiles and production efficiency, with ongoing commercialization efforts [1][2] - The industry is currently in the introduction and validation phase, with significant advancements in commercial viability since 2020 [2] Technological Pathways - Two main technological pathways for microbial protein production are identified: biomass fermentation and precision fermentation, with the latter being more complex but offering higher value-added products [2] - The commercial maturity of biomass fermentation is higher, particularly in meat and dairy products, while precision fermentation is still developing [2] Competitive Landscape - Innovative startups are leading in technological advancements, while traditional companies are leveraging their financial and operational synergies to enter the market [3][4] - Major players like Budweiser and Angel Yeast are building large-scale production capacities, significantly outpacing smaller startups [3] Future Outlook - Technology is the core competitive factor across all stages of microbial protein development, influencing product development, regulatory approval, and cost efficiency [4] - The ability to scale production and reduce costs will favor early entrants in the market, enhancing their competitive position [4]

Group 1 - Tianqi Materials reported a revenue of 7.03 billion yuan for the first half of 2025, a year-on-year increase of 28.97% [2][3] - The net profit attributable to shareholders was 268 million yuan, up 12.79% year-on-year, while the net profit excluding non-recurring items was 235 million yuan, reflecting a growth of 26.01% [2][3] - Basic earnings per share increased to 0.14 yuan, a rise of 16.67% compared to the previous year [3] Group 2 - New Zobang achieved a revenue of 4.25 billion yuan, marking an 18.58% increase year-on-year, with a net profit of 484 million yuan, up 16.36% [5][6] - The net profit excluding non-recurring items was 466 million yuan, showing an 8.16% increase [5][6] - Basic earnings per share rose to 0.64 yuan, a 16.36% increase from the previous year [6] Group 3 - Ruida New Materials reported a revenue of 975 million yuan, a decline of 7.36% year-on-year, with a net profit of 82 million yuan, down 24.19% [7][8] - The net profit excluding non-recurring items was 79 million yuan, reflecting a decrease of 27.57% [7][8] - The company experienced a negative cash flow from operating activities of 80 million yuan [8] Group 4 - Yongtai Technology reported a revenue of 2.61 billion yuan, a year-on-year increase of 21.97%, with a net profit of 59 million yuan, up 56.17% [10][11] - The net profit excluding non-recurring items was 23 million yuan, down 15.08% [10][11] - Basic earnings per share increased to 0.06 yuan, a 50% rise compared to the previous year [11] Group 5 - Shida Shenghua reported a revenue of 3.01 billion yuan, a year-on-year increase of 14.87%, but a net loss of 56 million yuan, a decline of 248.03% [13][14] - The net loss excluding non-recurring items was 57 million yuan, down 282.11% [13][14] - The company reported a positive cash flow from operating activities of 90 million yuan [14] Group 6 - Duofluor reported a revenue of 4.33 billion yuan, a decline of 6.65% year-on-year, with a net profit of 51 million yuan, down 16.55% [15][16] - The net profit excluding non-recurring items was a loss of 4.81 million yuan, reflecting a decrease of 179.71% [15][16] - Basic earnings per share decreased to 0.0441 yuan, down 15.19% [16] Group 7 - Tianji Co. reported a revenue of 1.07 billion yuan, a year-on-year increase of 19.16%, but a net loss of 52 million yuan, an improvement of 59% compared to the previous year [18][19] - The net loss excluding non-recurring items was 56 million yuan, down 56.04% [18][19] - The company reported a negative cash flow from operating activities of 131 million yuan [19] Group 8 - Huayu Pharmaceutical reported a revenue of 882 million yuan, a decline of 1.73% year-on-year, with a net loss of 5.81 million yuan, a decline of 116.23% [21][22] - The net loss excluding non-recurring items was 21.59 million yuan, down 247.06% [21][22] - The company reported a negative cash flow from operating activities of 169 million yuan [22] Group 9 - Haike New Source reported a revenue of 2.32 billion yuan, a year-on-year increase of 27.92%, but a net loss of 42 million yuan, an improvement of 61.21% [23][24] - The net loss excluding non-recurring items was 49 million yuan, down 56.57% [23][24] - The company reported a negative cash flow from operating activities of 248 million yuan [24] Group 10 - Hualu Hengsheng reported a revenue of 15.76 billion yuan, a decline of 7.14% year-on-year, with a net profit of 1.57 billion yuan, down 29.47% [26][27] - The net profit excluding non-recurring items was 1.56 billion yuan, reflecting a decrease of 30.29% [26][27] - Basic earnings per share decreased to 0.739 yuan, down 29.48% [27] Group 11 - Huasheng Lithium reported a revenue of 349 million yuan, a year-on-year increase of 72.02%, but a net loss of 72 million yuan [29] - The net profit excluding non-recurring items was a loss of 78 million yuan [29] - The company reported a negative cash flow from operating activities of 183 million yuan [29] Group 12 - Fuxiang Pharmaceutical reported a revenue of 514 million yuan, a decline of 24.58% year-on-year, with a net loss of 6.91 million yuan, an increase of 69.23% [31][32] - The net loss excluding non-recurring items was 32 million yuan, reflecting a decrease of 34.91% [31][32] - The company reported a negative cash flow from operating activities of 10 million yuan [32] Group 13 - Furui Co. reported a revenue of 2.59 billion yuan, a decline of 3.03% year-on-year, but a net profit of 246 million yuan, an increase of 10.92% [34][35] - The net profit excluding non-recurring items was 250 million yuan, reflecting a growth of 15.71% [34][35] - The company reported a positive cash flow from operating activities of 447 million yuan [35] Group 14 - The overall performance of companies in the electrolyte and raw material sector has been poor, with most companies reporting unsatisfactory financial results [36] - Except for Tianqi and New Zobang, other companies in the electrolyte sector have shown average performance [36] - Companies in the lithium hexafluorophosphate sector have reported significant losses, with net profits declining across the board [36]

Group 1 - The stock price of Fuxiang Pharmaceutical on August 27 was 10.05 yuan, down 0.59 yuan or 5.55% from the previous trading day [1] - The company primarily engages in the research, production, and sales of active pharmaceutical ingredients and intermediates for anti-infection drugs, while also expanding into lithium battery electrolyte additives and synthetic biology microbial protein [1] - Fuxiang Pharmaceutical is the largest supplier of sulbactam globally and the only domestic supplier in the sulbactam field certified by international standards [1] Group 2 - According to the company's 2025 semi-annual report, it achieved operating revenue of 515 million yuan in the first half of the year, a year-on-year decrease of 24.6%, with a net profit attributable to the parent company of -6.91 million yuan, an improvement from a loss of 22.46 million yuan in the same period last year [1] - In the lithium battery electrolyte additive business, the company has established an annual production capacity of 8,000 tons for VC products and 3,700 tons for FEC products [1] - The company has a production capacity of 1,200 tons per year in the microbial protein sector and is constructing a project with an annual capacity of 20,000 tons [1] Group 3 - On August 27, the net inflow of main funds into Fuxiang Pharmaceutical was 17.78 million yuan, accounting for 0.39% of the circulating market value; over the past five days, the cumulative net inflow was 20.96 million yuan, representing 0.46% of the circulating market value [2]

Core Viewpoint - The company has made significant progress in its strategic development, focusing on optimizing governance structures and enhancing operational efficiency while achieving a reduction in net losses during the first half of 2025 [5][6]. Company Overview - The company reported a revenue of 514.67 million yuan in the first half of 2025, with a net profit attributable to shareholders of -6.91 million yuan, reflecting a year-on-year reduction in losses by 15.55 million yuan [5][6]. Key Developments - The company has optimized its governance structure, ensuring continuity and stability through the re-election of the board and the appointment of senior management [6]. - The company’s new protein product successfully obtained GRAS certification in the U.S., facilitating its entry into international markets [6]. - The company was included in the first batch of the national bio-manufacturing landmark product list, showcasing its technological strength in the field of microbial protein [6]. Future Plans - For the second half of 2025, the company will focus on three main business divisions: pharmaceuticals, new energy, and synthetic biology, aiming to enhance marketing and R&D capabilities [7]. - The pharmaceutical division plans to deepen collaboration with key customers and enhance product development to improve market competitiveness [8]. - The new energy division aims to strengthen strategic partnerships and optimize production processes to reduce costs and enhance operational efficiency [8]. - The synthetic biology division will focus on commercializing its new protein product and expanding its market presence through innovative applications [9][10]. Product Development - The company is advancing its amino acid water-soluble fertilizer product, which utilizes by-products from its new protein production process, aiming for certification and market launch in the second half of 2025 [12].

汇总表 第 2 页 江西富祥药业股份有限公司 2025 年 1-6 月 非经营性资金占用及其他关联资金往来情况汇总表 ________ 单位：元 占用方与上市公司的 上市公司核算的 2025 年期初占用 2025 年 1-6 月偿 2025 年 6 月期末 占用形成原 非经营性资金占用 资金占用方名称 累计发生金额（不含 占用资金的 利 占用性质 关联关系 会计科目 资金余额 还累计发生金 额 占用资金余额 因 利息） 息(如有) 控股股东、实际控制人及其附属企业 小计 前控股股东、实际控制人及其附属企业 小计 其他关联方及附属企业 小计 总计 往来方与上市公司的 上市公司核算的 2025 年期初往来 2025 年 1-6 月偿 2025 年 6 月期末 往来形成原 其它关联资金往来 资金往来方名称 累计发生金额（不含 往来资金的 利 （经营性往来、 关联关系 会计科目 资金余额 还累计发生金 额 往来资金余额 因 利息） 息(如 有) 非经营性往来） 公司实际控制人控制 9,245.00 - 9,245.00 - 控股股东、实际控制人及其附属企业 南平铭正医药化学有限公司 应收账 款 货款 经营性往来 的公 ...

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) reported a decline in revenue for the first half of 2025, indicating challenges in its financial performance while showing improvements in net losses compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 515 million yuan, representing a year-on-year decrease of 24.58% [1] - The net loss attributable to shareholders of the listed company was 6.9112 million yuan, which narrowed by 69.23% year-on-year [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 32.1798 million yuan, a reduction of 34.91% compared to the previous year [1] - The basic loss per share was 0.01 yuan [1]

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 515 million yuan, representing a year-on-year decrease of 24.58% [1] - The net profit attributable to shareholders of the listed company was -6.91 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -32.18 million yuan [1] - Basic earnings per share were -0.01 yuan [1]

证券代码：300497 证券简称：富祥药业 公告编号：2025-057 江西富祥药业股份有限公司 关于2025年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司2025年半年度报告全文及摘要将于2025年8月27日在 中国证监会指定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露， 敬请投资者注意查阅。 特此公告。 江西富祥药业股份有限公司 2025 年 8 月 26 日 董事会 ...

江西富祥药业股份有限公司 2025 年半年度财务报告 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：江西富祥药业股份有限公司 单位：元 项目 期末余额 期初余额 流动资产： 货币资金 606,508,100.18 695,350,502.08 结算备付金 拆出资金 交易性金融资产 2,185,000.00 2,185,000.00 衍生金融资产 应收票据 27,664,255.58 42,783,498.32 应收账款 252,136,406.46 261,238,271.67 应收款项融资 165,605,297.04 194,141,196.88 预付款项 8,120,775.10 10,419,901.20 应收保费 应收分保账款 应收分保合同准备金 其他应收款 12,665,071.11 28,029,363.75 其中：应收利息 应收股利 买入返售金融资产 存货 471,593,590.60 421,053,194.07 其中：数据资源 合同资产 持有待售资产 一年内到期 ...

江西富祥药业股份有限公司 （一）实际募集资金金额、资金到位情况 截至 2025 年 6 月 30 日，公司本年度使用金额情况为： 经中国证券监督管理委员会出具的证监许可[2020]3231 号《关于同意江西富 祥药业股份有限公司向特定对象发行股票注册的批复》同意注册，本公司向特定 对象发行普通股（A 股）79,191,640.00 股，每股面值 1.00 元，发行价格 12.68 元 /股，共募集资金 1,004,149,995.20 元，扣除保荐承销发行费用人民币 10,000,000.00 元，扣除其他与发行权益性证券直接相关的外部费用 2,785,933.52 元，实际募集 资金净额为人民币 991,364,061.67 元。上述募集资金于 2020 年 12 月 31 日到位， 经立信会计师事务所（特殊普通合伙）验证，并由其出具信会师报字[2021]第 ZF10008 号验资报告，已存放于募集资金专户。公司对募集资金采取专户存储制 度，并与保荐机构、存放募集资金的开户银行签订了募集资金三方监管协议。 向特定对象发行股票募集资金使用情况对照表详见本报告附表 1。 （二）2025 年度募集资金使用情况及结 ...